NASDAQ$LPCN
Lipocine Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Lipocine announced financial results for the full year ended December 31, 2024.
Lipocine reported a net income of approximately $8,400 for the year ended December 31, 2024, a significant improvement from a net loss of $16.4 million in the prior year. The company's revenue for the year was $11.2 million, primarily driven by license and royalty revenue from partnerships.
- Lipocine reported a net income of approximately $8,400 for the year ended December 31, 2024, compared to a net loss of $16.4 million in 2023.
- Total revenues for the year ended December 31, 2024, were $11.2 million, primarily from license and royalty revenue.
- Research and development expenses decreased to $7.4 million in 2024 from $10.2 million in 2023, mainly due to the completion of the LPCN 1148 Phase 2 POC study.
- The company's cash, cash equivalents, and marketable investment securities stood at $21.6 million as of December 31, 2024.
Headline financials
Revenue & EPS history
Lipocine · Revenue · Quarterly
$11.2M
Forward guidance
Lipocine is advancing its product candidates, particularly LPCN 1154 for postpartum depression, with a planned Phase 3 study. The company is also exploring partnerships for several of its drug candidates to monetize non-core assets and expand market reach.
Tailwinds
- Initiating a Phase 3 safety and efficacy study for LPCN 1154 (oral brexanolone) for PPD in Q2 2025.
- Exploring partnerships for LPCN 1154, LPCN 2401, and LPCN 1148 to monetize non-core assets.
- TLANDO license agreement with Verity Pharma provides significant upfront and milestone payments.
- Positive data from the Phase 2 study of LPCN 2401 supports its potential as an adjunct or monotherapy for obesity management.
- LPCN 1148 received fast track designation from the US FDA for sarcopenia in decompensated cirrhosis patients.
Headwinds
- FDA requires a safety and efficacy study for LPCN 1154 for 505(b)(2) NDA submission, potentially extending development timelines.
- Risks associated with not being successful in developing product candidates.
- Potential for insufficient capital to complete development processes.
- Uncertainty in entering into partnerships or strategic relationships to monetize non-core assets.
- Safety and efficacy studies may not provide results that support NDA submission or FDA approval.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+0.7%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-3.6%
Avg return
30 days after
55%
28 / 51 earnings
Positive
+23.5%
Q3 2015
Best reaction
-22.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.6% | -4.1% | — | |
| Q4 2025 | +2.9% | -6.9% | -73.5% | |
| Q3 2025 | +3.1% | +12.9% | +23.0% | |
| Q2 2025 | +0.8% | -1.8% | -1.3% | |
| Q1 2025 | +7.0% | -2.9% | -16.5% | |
| Q4 2024 | -3.3% | -10.9% | -13.6% | |
| Q3 2024 | -21.5% | -15.8% | -15.8% | |
| Q2 2024 | -12.5% | -24.6% | -27.4% | |
| Q1 2024 | +9.7% | +10.3% | +55.1% | |
| Q4 2023 | +0.8% | +10.6% | +34.1% | |
| Q3 2023 | -6.0% | +10.3% | +1.7% | |
| Q2 2023 | -0.2% | -1.8% | -27.7% | |
| Q1 2023 | -4.6% | -21.9% | -4.9% | |
| Q4 2022 | -9.2% | -26.4% | -23.8% | |
| Q3 2022 | -3.2% | -2.8% | +3.6% | |
| Q2 2022 | -11.9% | -14.2% | -34.8% | |
| Q1 2022 | -6.2% | -4.1% | +13.6% | |
| Q4 2021 | +7.8% | +2.8% | -16.3% | |
| Q3 2021 | -0.8% | +0.8% | -5.9% | |
| Q2 2021 | +2.3% | +5.3% | -6.0% | |
| Q1 2021 | +0.0% | -1.4% | -12.2% | |
| Q4 2020 | +11.4% | +3.4% | +3.4% | |
| Q3 2020 | +4.9% | +1.4% | -4.9% | |
| Q2 2020 | -6.1% | +8.2% | -34.2% | |
| Q1 2020 | +6.2% | +18.2% | +44.0% | |
| Q4 2019 | -22.9% | -20.0% | +13.3% | |
| Q3 2019 | -14.5% | -50.8% | -56.0% | |
| Q2 2019 | +5.6% | +5.6% | +78.9% | |
| Q1 2019 | +1.6% | -3.2% | -19.9% | |
| Q4 2018 | +5.1% | +11.2% | +16.3% | |
| Q3 2018 | +8.7% | +6.7% | -7.3% | |
| Q2 2018 | +4.2% | +7.0% | +14.0% | |
| Q1 2018 | +15.6% | -28.6% | -19.5% | |
| Q4 2017 | -6.3% | -3.8% | +6.3% | |
| Q3 2017 | +2.3% | +3.9% | +0.6% | |
| Q2 2017 | +2.3% | -3.4% | -14.0% | |
| Q1 2017 | -4.1% | -12.0% | -14.2% | |
| Q4 2016 | -2.5% | +0.0% | -6.3% | |
| Q3 2016 | +13.0% | +15.6% | +16.9% | |
| Q2 2016 | +14.4% | +21.4% | -8.7% | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +8.0% | — | — | |
| Q3 2015 | +23.5% | — | — | |
| Q2 2015 | +15.9% | — | — | |
| Q1 2015 | +5.0% | — | — | |
| Q4 2014 | -11.1% | — | — | |
| Q3 2014 | +14.4% | — | — | |
| Q2 2014 | -2.1% | — | — | |
| Q4 2013 | +5.4% | — | — | |
| Q1 2014 | +5.4% | — | — | |
| Q3 2013 | -17.5% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro